Ftse Mib
34.608,59
-0,62%
DAX
18.726,76
-0,21%
S&P 500
5.312,70
0,09%
NASDAQ
16.803,66
0,05%
Bitcoin
69.774,78
-2,34%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Context Therapeutics Inc (CNTX) Context Therapeutics Inc (CNTX) Notizie

CNTX

Context Therapeutics (CNTX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CNTX
DataOraFonteTitoloSimboloCompagnia
16/05/202422:01Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:CNTXContext Therapeutics Inc
10/05/202422:00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CNTXContext Therapeutics Inc
08/05/202422:06GlobeNewswire Inc.Context Therapeutics Reports First Quarter 2024 Operating and Financial ResultsNASDAQ:CNTXContext Therapeutics Inc
08/05/202422:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CNTXContext Therapeutics Inc
02/05/202413:31GlobeNewswire Inc.Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76NASDAQ:CNTXContext Therapeutics Inc
02/05/202413:30GlobeNewswire Inc.Context Therapeutics Announces $100 Million Private PlacementNASDAQ:CNTXContext Therapeutics Inc
01/04/202413:30GlobeNewswire Inc.Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive CancersNASDAQ:CNTXContext Therapeutics Inc
21/03/202412:43GlobeNewswire Inc.Context Therapeutics Reports Full Year 2023 Operating and Financial ResultsNASDAQ:CNTXContext Therapeutics Inc
06/03/202413:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTXContext Therapeutics Inc
07/02/202422:24Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CNTXContext Therapeutics Inc
09/11/202322:15GlobeNewswire Inc.Context Therapeutics Reports Third Quarter 2023 Operating and Financial ResultsNASDAQ:CNTXContext Therapeutics Inc
31/10/202314:00GlobeNewswire Inc.Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76NASDAQ:CNTXContext Therapeutics Inc
27/09/202315:00GlobeNewswire Inc.Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:CNTXContext Therapeutics Inc
09/08/202322:10GlobeNewswire Inc.Context Therapeutics Reports Second Quarter 2023 Operating and Financial ResultsNASDAQ:CNTXContext Therapeutics Inc
01/08/202313:30GlobeNewswire Inc.Context Therapeutics to Participate in Two August 2023 Investor ConferencesNASDAQ:CNTXContext Therapeutics Inc
20/06/202314:36Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CNTXContext Therapeutics Inc
31/05/202322:53Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNTXContext Therapeutics Inc
10/05/202322:39GlobeNewswire Inc.Context Therapeutics Reports First Quarter 2023 Operating and Financial ResultsNASDAQ:CNTXContext Therapeutics Inc
03/04/202313:30GlobeNewswire Inc.Context Therapeutics to Participate in Two April 2023 Investor ConferencesNASDAQ:CNTXContext Therapeutics Inc
27/03/202322:04Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:CNTXContext Therapeutics Inc
22/03/202322:08GlobeNewswire Inc.Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline UpdatesNASDAQ:CNTXContext Therapeutics Inc
15/03/202312:30GlobeNewswire Inc.Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023NASDAQ:CNTXContext Therapeutics Inc
14/02/202322:05Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CNTXContext Therapeutics Inc
06/02/202313:30GlobeNewswire Inc.Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial CancerNASDAQ:CNTXContext Therapeutics Inc
31/01/202313:30GlobeNewswire Inc.Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast CancerNASDAQ:CNTXContext Therapeutics Inc
09/01/202313:30GlobeNewswire Inc.Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive CancersNASDAQ:CNTXContext Therapeutics Inc
04/01/202313:30GlobeNewswire Inc.Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline MilestonesNASDAQ:CNTXContext Therapeutics Inc
08/12/202217:35TipRanksH.C. Wainwright Sticks to Their Buy Rating for Context Therapeutics (CNTX)NASDAQ:CNTXContext Therapeutics Inc
08/12/202213:30GlobeNewswire Inc.Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast CancerNASDAQ:CNTXContext Therapeutics Inc
02/12/202212:15TipRanksContext Therapeutics (CNTX) Receives a Buy from H.C. WainwrightNASDAQ:CNTXContext Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CNTX

La tua Cronologia

NASDAQ
STOK
Stoke Therapeutics
COIN
XCHEUSD
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network